ArticleSkin appendage disorders2022
Postpartum Telogen Effluvium Unmasking Traction Alopecia.
Article in Skin appendage disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Translating umbilical cord blood extracellular vesicles into a novel therapy for postpartum alopecia: a mechanistic and preclinical review.Frontiers in immunology · 2026Review
- Particulate matter exposure induces maternal scalp hair loss after birth in C57/B6 mouse via alteration of inflammatory and apoptotic pathways.Frontiers in endocrinology · 2026Article
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
- Postpartum Telogen Effluvium Unmasking Additional Latent Hair Loss Disorders.The Journal of clinical and aesthetic dermatology · 2024Article
- Alopecias: Practical Tips for the Management of Biopsies and Main Diagnostic Clues for General Pathologists and Dermatopathologists.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Telogen effluvium (TE) is a type of diffuse hair shedding that occurs 2-3 months after an exposure or trigger. The excessive hair loss may "unmask" underlying hair loss disorders such as female pattern hair loss. Case Presentation: This is a case series of 3 patients with postpartum TE in which an underlying traction alopecia (TA) was revealed. Conclusion: TE can unmask underlying TA. Awareness of this phenomenon is critical to appropriate diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.